Transgene forced to delay start of Novartis-optioned anticancer trial
This article was originally published in Scrip
Executive Summary
Transgene has been forced to delay the start of its Phase IIb/III trial of its targeted immunotherapy product for non-small cell lung cancer, TG4010, by around 12 months to the end of this year following a meeting with the US FDA. The product is the subject of an option agreement signed with Novartis last year (scripintelligence.com, 10 March 2010)
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.